An inverse effect on ACLY and AMPK activity was identified upon treatment with a structurally different compound, ETC-1002 (8-hydroxy-2, 2, 14, 14-tetramethylpentadecanedioic acid), that has been developed for the treatment of dyslipidemia. Here, PRKAA1 is linked to metabolic syndrome.